TESARO, Inc.

Back to All Transactions

TESARO, Inc.
For more information regarding this transaction contact:
  • Dave McDonald Investment Banking 612.326.1268
  • Rob Martin Investment Banking 612.260.5850

Lake Street is pleased to announce it served as financial advisor for TESARO, Inc (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, in its offering of 5,347,500 shares of common stock at an offering price to the public of $81.00 per share, which included 697,500 shares of common stock sold pursuant to the full exercise of the underwriters' option. Gross proceeds were approximately $433.1 million. 

About TESARO:

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of patients with cancer. The Company’s key franchises include: (i) VARUBI™ - an NK1 receptor antagonist for prevention delayed chemotherapy-induced nausea and vomiting (CINV) including highly emetogenic (HEC) regiments; (ii) niraparib - a PARP inhibitor being developed for treatment of multiple solid tumors, with an extensive ovarian cancer focus; and (iii) an immuno-oncology (IO) franchise comprised of checkpoint inhibitors. TESARO is headquartered in Waltham, Massachusetts and was founded in 2010.

Contact

Mike Townley
Head of Investment Banking

612.326.1313

Email Mike
 

Dave McDonald
Head of Life Science Investment Banking

612.326.1268

Email Dave

 

Tim Klein

Investment Banking

612.260.6173

Email Tim

 

Rob Martin

Investment Banking

612.260.5850

Email Rob

 

Steve Rickman

Investment Banking

612.326.1985

Email Steve